Comments on: Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson’s disease target

Comments on: Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson’s disease target https://www.worldpharmatoday.com/press-releases/oncodesign-and-ipsen-enter-into-a-research-collaboration-for-the-development-of-new-therapeutic-agents-against-the-lrrk2-parkinsons-disease-target/ Magazine for the C-level Pharma Executives Wed, 04 Jan 2012 18:30:00 +0000 hourly 1 https://wordpress.org/?v=6.9.4